Genmab A/S Announces Lift of Zalutumumab Partial Clinical Hold

COPENHAGEN, Denmark, July 16, 2009 (GLOBE NEWSWIRE) -- Summary: The FDA Has Lifted the Partial Clinical Hold On Zalutumumab. Genmab A/S (Copenhagen:GEN) announced today that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on zalutumumab studies being conducted under an U.S. Investigational New Drug application. Enrollment of patients can now resume in the Phase II study in patients with head and neck cancer considered incurable with standard treatment and the Phase I/II front line study of zalutumumab in combination with chemo-radiation.